| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2025 | $21.00 | Outperform | Evercore ISI |
| 7/1/2025 | $25.00 | Overweight | Morgan Stanley |
| 7/1/2025 | $19.00 | Overweight | Analyst |
| 7/1/2025 | $23.00 | Buy | Needham |
| 7/1/2025 | $21.00 | Overweight | Barclays |
| 7/1/2025 | $29.00 | Buy | Goldman |
| 7/1/2025 | $27.00 | Buy | Canaccord Genuity |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00
Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00
Analyst initiated coverage of Omada Health with a rating of Overweight and set a new price target of $19.00
Barclays initiated coverage of Omada Health with a rating of Overweight and set a new price target of $21.00
Needham initiated coverage of Omada Health with a rating of Buy and set a new price target of $23.00
Goldman initiated coverage of Omada Health with a rating of Buy and set a new price target of $29.00
Canaccord Genuity initiated coverage of Omada Health with a rating of Buy and set a new price target of $27.00
Fastest customizable press release news feed in the world
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
10-Q - Omada Health, Inc. (0001611115) (Filer)
8-K - Omada Health, Inc. (0001611115) (Filer)
SCHEDULE 13G - Omada Health, Inc. (0001611115) (Subject)
8-K - Omada Health, Inc. (0001611115) (Filer)
424B4 - Omada Health, Inc. (0001611115) (Filer)
Revenue of $61 million, up 49%52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Highlights Total Members of 752,000, up 52% compared to the second quarter of 2024Revenue of $61 million, up 49% compared to the second quarter of 2024GLP-1 Companion Success, with strong growth in members being supported by Omada's GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United StatesOmada Horizon Day: In M
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI too
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
4 - Omada Health, Inc. (0001611115) (Issuer)
Live finance-specific insights
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l
Live Leadership Updates
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1 Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in